Synthetic Biology Manufacturing Market
Every Market-Reports.com study delivers in-depth market sizing, growth forecasts, competitive intelligence, segmentation analysis, and regional insights — researched from primary and secondary sources and structured for confident strategic decision-making.
Market Snapshot
2025 Market Size
US$ 12.5 billion
Estimated Base Value
2035 Forecast
US$ 55.7 billion
Projected Market Value
CAGR 2026–2035
16.1%
Compound Annual Growth
Largest Segment
Gene Synthesis Services
Fastest Growing Segment
Genome Synthesis & Engineering
Leading Region
Asia Pacific
Fastest Growing Region
Emerging Areas
Top Country
United States
By Market Share
18.5% market share
Key Players
Ginkgo Bioworks
Emerging Players
Asimov, AbSci
Market Definition & Overview
The Synthetic Biology Manufacturing Market within Pharmaceuticals encompasses the industrial-scale application of engineered biological systems for producing pharmaceutical products, intermediates, and active pharmaceutical ingredients (APIs). This market leverages genetically modified organisms, engineered cell lines, or cell-free systems to synthesize complex biologics, small molecule drugs, vaccines, and advanced therapies. It covers the entire manufacturing workflow, from strain engineering and bioprocess development to large-scale fermentation, purification, and quality control, focusing on enhancing production efficiency, sustainability, and the creation of novel drug compounds for human health applications.
Scope
- Global market analysis across all major geographic regions.
- Exclusive focus on manufacturing applications within the pharmaceutical industry.
- Study period covering market trends and forecasts from 2023 to 2033.
Inclusions
- Manufacturing of recombinant therapeutic proteins and biologics using engineered systems.
- Production of pharmaceutical small molecules via synthetic biology pathways.
- Synthetic biology-driven platforms for vaccine and advanced therapy manufacturing.
- Development and scale-up of genetically engineered cell lines and microorganisms for drug production.
- Contract manufacturing organizations (CMOs) offering synthetic biology services for pharma.
- Bioprocess optimization and automation solutions specifically for synthetic biology pharma manufacturing.
Exclusions
- Synthetic biology applications in non-pharmaceutical sectors such as biofuels or agriculture.
- Traditional chemical synthesis of pharmaceutical products without synthetic biology integration.
- Discovery-phase synthetic biology research not directly focused on manufacturing processes.
- Medical devices or diagnostics that do not involve synthetic biology in their production.
- Clinical trial services unrelated to the manufacturing of synthetic biology-derived drugs.
Market Size Forecast
Executive Summary
• The Synthetic Biology Manufacturing market is valued at $12.5 Bn in 2025 and is forecast to reach $55.7 Bn by 2035, reflecting a robust CAGR of 16.1% as demand accelerates across every major segment and region over the ten-year outlook.
• Gene Synthesis Services leads the segment breakdown by current market share, underscoring where the bulk of near-term revenue and competitive activity within this market is concentrated today.
• Asia Pacific commands the largest regional share at 38.0%, while Emerging Areas is expanding the fastest at a 10.0% CAGR, signalling where future growth is shifting.
• United States remains the single largest country-level market at 18.5% of global share, anchoring overall demand within its home region throughout the forecast period.
• Industry consolidation is accelerating, as platform companies acquire specialized expertise to build end-to-end manufacturing solutions, positioning them for dominance across diverse therapeutic applications and regional markets.
• AI-driven design and advanced bioprocessing are accelerating drug discovery and development, unlocking new therapeutic modalities and driving market expansion across oncology, rare diseases, and infectious diseases globally.
• Significant strategic investments are now prioritizing the establishment of diversified, regionally distributed supply chains and specialized biomanufacturing infrastructure to enhance resilience and mitigate future geopolitical risks.
• North America and Europe retain R&D leadership, yet Asia-Pacific is rapidly solidifying its role as a pivotal manufacturing hub, driven by scalable infrastructure investments and a burgeoning regional market for advanced biopharmaceuticals.
• Streamlined regulatory pathways, increasingly tailored for advanced biologics, are poised to accelerate market entry for novel synthetic biology-derived therapeutics, fostering an environment of rapid innovation and broader patient access.
• Cross-sector collaborations between pharmaceutical giants and specialized synbio startups are intensifying, strategically leveraging proprietary platforms to diversify pipelines and accelerate advanced therapy development, redefining competitive leadership.
Key Market Takeaways
Critical findings and data points from this market research study.
Market Valuation
The Synthetic Biology Manufacturing market was valued at a substantial $12.5 billion in the base year.
Strong Market Projection
This market is projected for significant expansion, expected to reach $55.7 billion by the forecast year.
High Growth Rate
Such rapid growth is underpinned by an impressive Compound Annual Growth Rate (CAGR) of 16.1% over the forecast period.
Pharmaceutical Sector Driver
The increasing adoption of synthetic biology manufacturing within the pharmaceuticals industry is a primary catalyst for the observed market growth.
Leading Segment Contribution
Biopharmaceutical applications, including the development of novel therapeutics and vaccines, are key leading segments contributing to the market's expansion.
Key Technological Trend
Continuous advancements in gene editing technologies and high-throughput screening methods represent a notable trend propelling the market forward.
Market Dynamics
Market Trends
- AI/ML integration accelerates synthetic biology design and discovery.
- Cell-free synthetic biology systems gain traction for efficiency.
- Sustainability becomes a key focus in biomanufacturing processes.
- Synthetic biology expands into personalized medicine applications.
Growth Drivers
- Growing demand for advanced biologics and cell therapies.
- Rapid advancements in gene editing and DNA synthesis technologies.
- Need for more cost-effective and efficient drug manufacturing.
- Increasing R&D funding for synthetic biology applications.
Restraints
- High development costs hinder market entry for many companies.
- Complex regulatory frameworks create significant approval hurdles.
- Ethical concerns surrounding gene editing slow public adoption.
- Scaling production of synthetic biology products remains a challenge.
Opportunities
- Developing novel therapeutics and vaccines using synthetic biology.
- Expanding applications into new and underserved disease areas.
- Strategic collaborations enhance drug discovery and production.
- Optimizing biomanufacturing for improved yield and purity.
Market Dynamics Framework · 2026–2035
Need Custom Data for This Market?
Get tailored segmentation, deeper competitive intelligence, or region-specific deep dives from our analyst team.
Market Segmentation
| Segment | Sub-segments |
|---|---|
| By Type | Gene Synthesis ServicesOligonucleotide SynthesisGenome Synthesis & EngineeringSynthetic Biology PlatformsFoundry ServicesEnabling Enzymes & KitsSynthetic Cells & OrganismsBiofoundry Equipment |
| By Technology | CRISPR Gene EditingMetabolic EngineeringBioinformatics & Computational DesignDNA Synthesis & Assembly TechnologiesCell-Free Synthetic BiologyDirected EvolutionLaboratory Automation & Robotics |
| By Application | Drug Discovery & DevelopmentTherapeutic Proteins & BiologicsVaccine Development & ProductionGene & Cell TherapiesDiagnostics & BiosensorsAdvanced Biomanufacturing of ApisRegenerative Medicine |
| By End-User | Pharmaceutical CompaniesBiotechnology CompaniesAcademic & Research InstitutesContract Research OrganizationsContract Manufacturing OrganizationsDiagnostic Laboratories |
| By Process | Design & Modeling PhaseBuild PhaseTest & Characterization PhaseLearn & Optimization PhaseUpstream ProcessingDownstream Processing |
| By Offering Model | Custom Synthesis & Engineering ServicesIntegrated Design-Build-Test-Learn ServicesPlatform & Software SubscriptionsReagent & Kit SalesContract Biomanufacturing ServicesConsulting & Data Analytics Services |
Regional Analysis
- North America leads the synthetic biology manufacturing market, fueled by significant R&D investments, a high concentration of biotechnology and pharmaceutical firms, and robust academic collaborations. Its advanced infrastructure and strong government support further solidify this dominant position in innovation.
- Asia-Pacific is emerging as the fastest-growing region in synthetic biology manufacturing, driven by escalating healthcare investments, expanding biopharmaceutical production capacities, and supportive government initiatives. A growing demand for advanced therapies and a large consumer base propel this rapid market expansion.
- Europe demonstrates an emerging trend in sustainable biomanufacturing within the synthetic biology sector. The region is increasingly focusing on green chemistry principles and circular economy models to develop environmentally friendly production processes. This emphasis ensures both innovation and ecological responsibility.
Asia Pacific
8.5% CAGR
$4.8 Bn
38% share
- Driven by robust pharmaceutical manufacturing bases in China and India, increasing R&D investments, and growing demand for affordable biologics, the region is a key hub for synthetic biology production.
- Favorable government initiatives and a large patient population further fuel its market expansion.
North America
7.2% CAGR
$3.6 Bn
29% share
- A leader in synthetic biology innovation and investment, North America benefits from a strong biotech ecosystem, advanced research infrastructure, and significant venture capital funding.
- The presence of numerous pharmaceutical giants and academic institutions drives continuous technological advancements.
Europe
6.8% CAGR
$2.9 Bn
23% share
- Europe boasts a well-established pharmaceutical industry, strong regulatory frameworks, and significant public and private funding for synthetic biology research.
- Countries like Germany, the UK, and Switzerland are at the forefront of developing and implementing synthetic biology solutions in manufacturing.
Latin America
9.5% CAGR
$625.0 Mn
5% share
- While smaller, this region shows promising growth in synthetic biology manufacturing, particularly in countries like Brazil and Mexico, driven by increasing healthcare expenditure and a push for local drug production.
- International collaborations and technology transfer are key growth drivers.
Middle East & Africa
9.0% CAGR
$375.0 Mn
3% share
- This region is witnessing nascent but accelerating adoption of synthetic biology technologies, primarily in the GCC countries and South Africa, supported by government diversification strategies and investment in biotechnology.
- Focus is often on local vaccine production and biopharmaceutical development.
Emerging Areas
10.0% CAGR
$250.0 Mn
2% share
- Comprising smaller, nascent geographies, these areas exhibit the highest growth potential from a very low base, driven by increasing awareness, capacity building initiatives, and international aid in healthcare infrastructure.
- Early-stage adoption is seen in areas requiring basic pharmaceutical and vaccine production.
Country Analysis
United States and Brazil represent the largest country-level markets, with growth across the remaining countries shaped by local regulatory, infrastructure, and demand-side factors specific to each geography.
| # | Country | Market Size | CAGR | Key Driver |
|---|---|---|---|---|
| 1 | United States | $2.3 Bn | 9.5% | The U.S. leads in synthetic biology manufacturing for pharmaceuticals due to its robust R&D, significant venture capital funding, and a high concentration of biotech and pharmaceutical companies driving innovation. |
| 2 | Brazil | $187.5 Mn | 7.5% | Brazil represents the largest pharmaceutical market in South America, with increasing investments in biotech R&D and manufacturing, aiming to reduce reliance on imported pharmaceutical ingredients. |
| 3 | Germany | $725.0 Mn | 8.7% | Germany's strong chemical and pharmaceutical industry, coupled with extensive research in biotechnology and advanced manufacturing infrastructure, positions it as a major European contributor to synthetic biology manufacturing. |
| 4 | China | $1.8 Bn | 10.5% | China is rapidly expanding its synthetic biology manufacturing capabilities, driven by massive government investment, a large talent pool, and a strategic focus on becoming a global leader in biotechnology. |
| 5 | Israel | $125.0 Mn | 10.2% | Israel is a leading innovation hub with a highly dynamic biotech sector, strong R&D in synthetic biology, and numerous startups developing novel pharmaceutical solutions. |
Countries Covered (23)
United States, Canada, Mexico, Brazil, Argentina, Rest of South America, Germany, United Kingdom, France, Switzerland, Netherlands, Rest of Europe, China, Japan, India, South Korea, Taiwan, Singapore, Australia, Rest of Asia Pacific, Israel, Saudi Arabia, Rest of Middle East & Africa
Competitive Landscape
| # | Company | Share | Key Strategy | Key Note | Key Developments | Key Products |
|---|---|---|---|---|---|---|
| 1 | Ginkgo Bioworks | 5.7% | Expand its cell programming platform through broad partnerships across diverse industries to enable customers to develop new biological products. | Operates a highly automated biological foundry for custom organism engineering at industrial scale. | Acquired Zymergen to integrate its automation technologies and expand its platform capabilities in metabolic engineering. | Biosecurity PlatformCell Programming PlatformFoundry Services+1 |
| 2 | Amyris | 5.4% | Leverage its proprietary fermentation technology to produce sustainable, high-performance ingredients for health, beauty, and wellness markets. | Pioneered the industrial production of sustainable squalane from sugarcane through synthetic biology. | Filed for Chapter 11 bankruptcy in August 2023 to restructure operations, focusing on its core biotech platform and divesting consumer brands. | SqualaneHemisqualaneRebM+1 |
| 3 | Twist Bioscience | 5.1% | Revolutionize synthetic biology through its silicon-based DNA writing platform, enabling high-throughput, accurate, and cost-effective DNA synthesis. | Utilizes a proprietary silicon platform to miniaturize and parallelize DNA synthesis, vastly increasing throughput and reducing costs. | Expanded its DNA data storage capabilities and partnerships, demonstrating the long-term potential of this novel technology. | Synthetic DNAOligonucleotide PoolsGene Fragments+1 |
| 4 | Codexis | 4.9% | Apply its CodeEvolver® directed evolution platform to engineer novel enzymes for biopharmaceutical manufacturing, food ingredients, and other industrial applications. | Specializes in engineering and optimizing enzymes for specific industrial and therapeutic applications using its proprietary platform. | Partnered with companies like Takeda and Nestle Health Science for enzyme development in therapeutic and nutritional applications. | CodeEvolver PlatformProtein Engineering ServicesEnzymes for Pharmaceutical Manufacturing+1 |
| 5 | Novozymes | 4.6% | Lead the market in biological solutions by continuously innovating and expanding its portfolio of enzymes and microbes for industrial applications. | Global leader in enzyme and microbial technology for a wide range of industries including food, feed, energy, and household care. | Completed its merger with Chr. Hansen, forming Novonesis, to create a global biosolutions powerhouse. | Industrial EnzymesBiopharmaceutical IngredientsProbiotics+1 |
Market Positioning Map
Market share vs. growth outlook — bubble size is market share, bubble color is relative profitability
Companies Profiled (20)
Ginkgo Bioworks, Amyris, Twist Bioscience, Codexis, Novozymes, Lonza, Sartorius, Merck KGaA, Evonik, DSM-Firmenich, Catalent, GenScript Biotech, Synthego, Inscripta, Arzeda, Conagen, Antheia, Wacker Chemie, Solvay, Precigen
The global Synthetic Biology Manufacturing market features a competitive landscape led by Ginkgo Bioworks, Amyris, Twist Bioscience, Codexis, Novozymes, and Lonza, among other established and emerging players. Market participants continue to compete on product innovation, pricing strategy, geographic expansion, and strategic partnerships to strengthen their position in this evolving market.
* Market share estimates based on revenue analysis, primary interviews, and secondary research.
Company Profiles
Ginkgo Bioworks
Amyris
Twist Bioscience
Codexis
Novozymes
Lonza
Sartorius
Merck KGaA
Evonik
DSM-Firmenich
Catalent
GenScript Biotech
Synthego
Inscripta
Arzeda
Conagen
Antheia
Wacker Chemie
Solvay
Precigen
* Classification reflects relative market share and maturity, derived from revenue analysis and public disclosures.
Ready to Make Data-Driven Decisions?
Purchase the full report or request a custom engagement. Get analyst support, scenario modelling, and real-time dashboard access.
Recent Market Developments
Ginkgo Bioworks and Merck Expand Enzyme Engineering Partnership
Ginkgo Bioworks announced an expanded collaboration with Merck to accelerate the discovery and optimization of novel enzymes for pharmaceutical manufacturing processes. This partnership leverages Ginkgo's expertise in synthetic biology to improve the efficiency and sustainability of drug production.
Twist Bioscience Launches New mRNA Synthesis Solution
Twist Bioscience introduced its advanced mRNA Synthesis Solution, designed to provide high-quality and high-throughput mRNA for therapeutic development and manufacturing. This launch significantly enhances capabilities for companies developing mRNA vaccines and therapeutics.
ElevateBio Announces Major Cell & Gene Therapy Manufacturing Expansion
ElevateBio unveiled plans for a significant expansion of its BaseCamp manufacturing facility, boosting capacity for integrated cell and gene therapy development and production. This move addresses the growing demand for scalable and high-quality manufacturing solutions in the advanced therapies sector.
Synlogic Partners with Roche for Synthetic Biotics Development
Synlogic entered into a strategic collaboration with Roche to develop novel synthetic biotics for the treatment of various diseases. This partnership combines Synlogic's synthetic biology platform with Roche's drug development expertise to create new living therapeutic products.
Report Data Parameters
| Parameter | Value |
|---|---|
| Base Year | 2025 |
| Forecast Year | 2035 |
| Historical Period | 2019–2025 |
| Market Size (Base Year) | $12.5 Bn |
| Market Size (Forecast) | $55.7 Bn |
| CAGR | 16.1% |
| Forecast Period | 2026–2035 |
| Geography | Global |
| Countries Covered | 23 Countries |
| Segments Covered | 6 Segments, 40 Sub-segments |
| Companies Profiled | 20 Companies |
Report Value
Why Choose This Report
Complete Market Size
Accurate market sizing with historical data and a 10-year forecast across all scenarios.
Segment Analysis
Deep-dive segmentation by product, application, end-user, and technology verticals.
Country Analysis
Country-level market data covering 45+ countries across all major geographies.
Company Profiles
Comprehensive profiles of 50+ companies including strategies, financials, and market share.
Market Share
Detailed competitive market share analysis with trend mapping and benchmarking.
Competitive Intelligence
SWOT, Porter's Five Forces, and competitive positioning across market leaders.
Scenario Analysis
Three-scenario modelling (Base / Optimistic / Conservative) with CAGR decomposition.
Regulatory Review
Regulatory landscape, compliance requirements, and policy impact analysis by region.
Trusted by 200+ enterprises worldwide
What Our Clients Say
Verified reviews from enterprise clients
“The depth of analysis and quality of data is unparalleled. This report directly informed our $50M market expansion strategy and helped us prioritise the right geographies.”
Sarah Chen
VP Strategy, Fortune 500 Manufacturer
“Exceptional research quality. The competitive landscape section alone saved our team months of primary research effort and gave us a clear view of the opportunity.”
Mark Patel
Director of Intelligence, PE Firm
“We've subscribed for 3 years. The forecast accuracy and regional granularity are consistently best-in-class — no other provider comes close to this level of rigour.”
Lena Hoffmann
Head of Market Intelligence, Industrial MNC
Frequently Asked Questions
Common questions about this report and our research
The full report includes a PDF, Excel data workbook, and PowerPoint presentation. Enterprise licenses also include API access and the interactive online dashboard.
Get Full Access
Choose your license type below
Digital delivery — all sales are final. See our Refund Policy and Terms & Conditions.
What's Included